Dixon Technologies (India) Ltd. (DIXON) Gets a Buy from Nomura
In a report released yesterday, Siddhartha Bera from Nomura maintained a Buy rating on Dixon Technologies (India) Ltd. (DIXON – Research Report), with a price target of INR21,409.00. The company's shares closed yesterday at INR14,473.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Bera covers the Consumer Goods sector, focusing on stocks such as Dixon Technologies (India) Ltd., Voltas Limited, and Bhartiya International Limited. According to TipRanks, Bera has an average return of 0.2% and a 44.44% success rate on recommended stocks.
Dixon Technologies (India) Ltd. has an analyst consensus of Moderate Sell, with a price target consensus of INR14,286.67.
The company has a one-year high of INR19,149.80 and a one-year low of INR10,613.00. Currently, Dixon Technologies (India) Ltd. has an average volume of 59.17K.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Stock market today: Dow, S&P 500 and Nasdaq futures rise as stocks set to end June with a bang
US stock futures edged higher Sunday evening, setting up the major indexes for more records to end one of the most volatile first halves of a year in recent memory. Futures tied to the Dow Jones Industrial Average (YM=F) rose around 0.5%. Contracts on the S&P 500 (ES=F) gained 0.2%, and Nasdaq 100 (NQ=F) futures ticked up 0.3%. Several of Trump's economic agenda items are in focus this week. A July 9 deadline looms before the possible resumption of Trump's unilateral tariffs, which Trump on Sunday said he didn't think he'd "need to" extend. On the trade front, India has extended its Washington visit to finalize a deal. Administration officials last week confirmed a trade framework with China was in place, bolstering investor sentiment despite a late-Friday dip triggered by Trump's abrupt halt to talks with Canada, citing its digital tax policy. Meanwhile, market watchers are closely following Senate negotiations over Trump's proposed $4.5 trillion tax cut bill. The measure, which passed a procedural vote Saturday, could face a tough path in the House. The Congressional Budget Office estimates it would add $3.3 trillion to the deficit over a decade. For the market, June's gains have been substantial, fueled by optimism surrounding global trade and easing fears over tariffs. The S&P 500 (^GSPC) is up over 4%, the Nasdaq Composite (^IXIC) has surged over 5.5%, and the Dow (^DJI) has climbed 3.5%. On Friday, all three major indexes closed higher, with the S&P and Nasdaq reaching new record highs for the first time since February — the start of the year's tariff-fueled stock swings. All three major indexes are up at least 3% so far this year. Looking ahead, investors will monitor key Chinese PMI data due Monday to gauge how the ongoing trade war is affecting Asia's largest economy. Despite lingering uncertainties, the broader market remains upbeat heading into the new quarter and second half.
Wall Street Journal
an hour ago
- Wall Street Journal
KKR to Sell Stake in Indian Pharma Company for $1.4 Billion
Private-equity firm KKR has agreed to sell its entire stake in India-listed J.B. Chemicals & Pharmaceuticals for $1.4 billion. Under the deal, KKR will sell its 46.39% stake to Torrent Pharmaceuticals 500420 3.68%increase; green up pointing triangle, the private-equity firm said late Sunday. The two pharmaceutical firms will then merge through a scheme of arrangement.
Associated Press
2 hours ago
- Associated Press
Torrent Pharma to Acquire Controlling Stake in J. B. Chemicals & Pharmaceuticals from KKR
MUMBAI, India--(BUSINESS WIRE)--Jun 29, 2025-- Torrent Pharmaceuticals Limited ('Torrent') and global investment firm KKR today announced that Torrent has entered into definitive agreements to acquire controlling stake in J. B. Chemicals and Pharmaceuticals ('JB Pharma') from KKR at an Equity Valuation of INR 25,689 crores (on fully diluted basis), followed by a merger of the two entities. The transaction marks a significant step in Torrent's ambition to create a future-ready, diversified healthcare platform combining a deep chronic segment heritage with emerging international CDMO capabilities. This press release features multimedia. View the full release here: The transaction will be executed in 2 phases: Samir Mehta, Executive Chairman, Torrent, commented: 'We are pleased to have on board the JB Pharma heritage and build on the platform for the future. Torrent's deep India presence and JB Pharma's fast growing India business, combined with the CDMO and international footprint offers immense potential to scale both revenue and profitability. This strategic alignment furthers our goal of strengthening our presence in the Indian pharma market, and build a larger diversified global presence. Moreover, the CDMO platform provides a new long-term avenue of growth for Torrent.' Gaurav Trehan, Co-Head of Asia Pacific and Head of Asia Pacific Private Equity, KKR, and CEO of KKR India, said: 'JB Pharma's transformation under our stewardship is a testament to KKR's ability to scale high-quality companies. We are proud to have collaborated with JB Pharma's management team, led by Nikhil Chopra, to bring the breadth of KKR's global experience and operational expertise to support the company's organic and inorganic growth, and help JB Pharma become one of India's fastest growing branded pharmaceutical companies. We believe the company is well-positioned for continued growth ahead and wish the team every success in its next chapter with Torrent.' Nikhil Chopra, Chief Executive Officer and Whole Time Director of JB Pharma, remarked: 'Over the past five years, JB Pharma has emerged as one of India's fastest growing pharmaceutical players, owing to KKR's strategic guidance, stewardship of our independent directors and a focused strategic and executional excellence by the management team. We have built a strong foundation to deliver market-leading growth, as well as consistent improvement in profitability in the medium and long term. As we now enter a new chapter alongside Torrent Pharmaceuticals, we are confident that the combined strengths of our organizations will unlock greater opportunities to enhance healthcare access across our markets.' Strategic Rationale for Acquisition Transaction Structure & Approvals View source version on CONTACT: Media ContactsFor KKR: Wei Jun Ong +65 6922 5813 [email protected] Torrent Pharma: Jayesh Desai +91 9824501396 KEYWORD: INDIA ASIA PACIFIC INDUSTRY KEYWORD: FINANCE HEALTH PROFESSIONAL SERVICES PHARMACEUTICAL ASSET MANAGEMENT SOURCE: KKR Copyright Business Wire 2025. PUB: 06/29/2025 11:53 AM/DISC: 06/29/2025 11:53 AM
